BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.

By Mingzhao Xing, W. Westra, R. Tufano, Y. Cohen, E. Rosenbaum, K. Rhoden, K. Carson, V. Vasko, A. Larin, G. Tallini and 12 more. Journal of Clinical Endocrinology and Metabolism, 2005

1,008 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/8c47adf18c5ab4723ac666027a23c0d8ce57de4d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Y. Nikiforov
2. M. Nikiforova
3. Mingzhao Xing

In Surgery

1. Y. Nikiforov
2. M. Nikiforova

Citations in the corpus

• MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. (2008, background): “However, each of these mutations is associated with distinct coding gene expression profiles, phenotypical characteristics, and biological properties of PCs (19, 32, 33).”
• 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer (2009, positive): “Some studies (564,565), but not all (566–568), have demonstrated that the BRAF mutation is an independent predictor of risk of 44 HAUGEN ET AL.”
• Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer (2013, methodology): “0 cm or smaller, BRAF V600E was also associated with mortality, consistent with previous findings that this mutation could be associated with aggressive tumor features even in conventionally low-risk patients.(14,18,31) In such low-risk categories, however, the absolute mortality rate is low.”
• Phase II trial of sorafenib in advanced thyroid cancer. (2008, background): “In thyroid cancer, BRAF has been found in 29% to 69% of papillary thyroid cancers(13,15,16) and has been associated with aggressive features including extrathyroidal extension and advanced stage.(17,18) RAS mutations and RET/PTC translocations associated with some thyroid cancers also result in aber”
• BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. (2014, methodology): “The pathologic diagnoses of PTC in our patients were formally established.(11) Disease stages of PTC were defined on the basis of the American Joint Committee on Cancer staging system.”